Failed 2026

    IO Biotech

    A single pivotal trial narrowly missing statistical significance can be as fatal to a biotech's near-term viability as an outright failure, especially when regulators require an entirely new registrational study.

    TL;DR — Failure Post-Mortem

    IO Biotech was a Biotechnology startup founded in 2014 in USA. It raised $170M before collapsing in 2026 — 12 years of runway burned. IdeaProof's AI Failure Score: 6/100, driven by filed for chapter 7 bankruptcy. The shutdown affected employees, investors, and the broader Biotechnology ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.

    Why did IO Biotech fail?

    IO Biotech failed in 2026 after 12 years of operation, losing $170M in raised capital. The root cause was filed for chapter 7 bankruptcy. Key lesson: A single pivotal trial narrowly missing statistical significance can be as fatal to a biotech's near-term viability as an outright failure, especially when regulators require an entirely new registrational study.

    Verifiable facts
    Sourced
    Founded → Closed

    2014 → 2026

    Funding Raised

    $170M

    Industry

    Biotechnology

    Country

    USA

    IdeaProof AI Failure Score

    6/100
    Market Fit Risk
    Burn Rate Risk
    Founder Risk

    What Happened: The Timeline

    2025-08

    Phase 3 IOB-013 trial narrowly misses PFS significance

    2025-09

    FDA recommends against BLA; company restructures

    Root Causes

    IO Biotech, a New York-based clinical-stage biotech, developed Cylembio, a therapeutic cancer vaccine to combine with Merck's Keytruda as first-line treatment for advanced melanoma. The pivotal Phase 3 trial IOB-013 evaluated Cylembio+Keytruda vs Keytruda alone. In August 2025, IO Biotech announced the trial showed clinically meaningful improvement in progression-free survival but 'narrowly missed' statistical significance. Despite this, IO Biotech initially pursued FDA approval. In September 2025, following a pre-BLA meeting, the FDA recommended against a BLA submission, urging IO Biotech to design a new registrational study. IO Biotech announced restructuring and workforce reduction.

    Key Lessons Learned

    1. Phase 3 trial (IOB-013) narrowly missed statistical significance on progression-free survival

    Phase 3 trial (IOB-013) narrowly missed statistical significance on progression-free survival — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    2. FDA rejected pre-BLA pathway, recommending a new registrational study instead

    FDA rejected pre-BLA pathway, recommending a new registrational study instead — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    3. High cash burn on a single-asset late-stage program without a backup approval route

    High cash burn on a single-asset late-stage program without a backup approval route — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    Frequently Asked Questions

    Sources & Confidence

    Every data point is tagged with its source type and our confidence in it. How we grade sources.

    Additional references

    Could This Failure Have Been Prevented?

    IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank IO Biotech.

    Related Failures